Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494
Condition: Lymphoma
MeSH terms: Lymphoma; Lymphoma, Large B-Cell, Diffuse
Study type: Observational

Summary: 
      RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help
      doctors identify and learn more about biomarkers related to cancer. It may also help doctors
      understand how patients respond to treatment.

      PURPOSE: This laboratory study is looking at biomarkers using tissue samples from older
      patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or
      without rituximab on clinical trial ECOG-E4494.
    

Detailed description: 
      OBJECTIVES:

        -  To construct tissue microarrays (TMA) using tissue samples from older patients with
           diffuse large B-cell lymphoma treated with standard CHOP chemotherapy (cyclophosphamide,
           doxorubicin, vincristine, and prednisone) with or without rituximab on clinical trial
           ECOG-E4494.

        -  To allow this TMA resource to be included in a large international effort (the Lunenburg
           Lymphoma Biomarker Consortium [LLBC]), partnering with several other similar randomized
           trials (EORTC, HOVON, GELA, MINT) in order to properly power and bring standardization
           to the study of biomarkers in lymphoma.

        -  To evaluate the clinical impact and prognostic importance of a number of biomarkers,
           including Bcl-2, Bcl-6, CD10, FOXP1, MUM1, Ki-67, CD5, and HLA-Dr.

        -  To determine the prognostic impact of clinical International Prognostic Index (IPI)
           variables in a large international study.

        -  To determine the relationship between different biomarkers and clinical predictors.

        -  To establish the TMA (using tissue samples from patients treated on clinical trial
           ECOG-E4494) as a resource for future ECOG-driven studies and for validation of novel
           biomarkers as they become recognized and available.

      OUTLINE: Patients are stratified according to prior treatment (CHOP chemotherapy
      [cyclophosphamide, doxorubicin, vincristine, and prednisone] or CHOP-like chemotherapy vs
      CHOP chemotherapy with or without rituximab).

      Tissue microarrays will be constructed using tissue samples previously collected from
      patients treated on clinical trial ECOG-E4494. Tissue microarrays will be used for biomarker
      studies.
    

Intervention name(s): laboratory biomarker analysis
Intervention type(s): Other
Observational model: Other
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Samples submitted for research from patients participating in E4494
      
Keywords: contiguous stage II adult diffuse large cell lymphoma; noncontiguous stage II adult diffuse large cell lymphoma; recurrent adult diffuse large cell lymphoma; stage I adult diffuse large cell lymphoma; stage III adult diffuse large cell lymphoma; stage IV adult diffuse large cell lymphoma